In each study.

Davis. ‘Our objective in the Parkinson’s study was that had to explore safety and tolerability of aplindore across various titration schedules and dose ranges in separate groups of very pleased to very pleased not only successfully achieving this primary objective, however. Addition a strong and consistent effectiveness response reaction further inform our view of doses to take in the next study. ‘.. In each study, aplindore demonstrated highly significant efficacy and was well tolerated. Neurogen believes aplindore the dopamine partial agonist controlled release profile may be better tolerated, to deal with fewer side effects and greater dosing flexibility, than existing drugs for RLS and Parkinson’s disease. Side effects of RLS drugs that are currently on the market or in late-stage development of of daytime sleepiness, dizziness and nausea.

Restless legs syndromethe RLS study was a placebo-controlled, single-blind, multicenter trial evaluating the efficacy, safety and tolerability of single doses of aplindore compared to placebo. The primary efficacy endpoint was the mean change in the Periodic Limb Movement Index during sleep from baseline to the highest achieved aplindore dose. In this study, aplindore achieved statistically significant results compared with placebo at all doses tested. In addition, aplindore also with an incidence of adverse events similar to placebo as tolerated at doses up to 0.2 mg.Courtesy can total daily Women’s Health Policy Reports display, search the archives or sign up for email supply here to emphatically. To every day Women’s Health policy coverage is a free service the National Partnership for Women & Families.

Other entries from category "staff":

Random entries